aTyr Pharma to be Added to the Russell 2000® and Russell 3000® Indexes

Group 1 - aTyr Pharma, Inc. is expected to be added to the Russell 2000 Index and the Russell 3000 Index effective after the U.S. market close on June 27, 2025, as part of the 2025 Russell U.S. Indexes annual reconstitution [1] - The Russell 3000 Index tracks the performance of the largest 3,000 publicly traded U.S. companies, while the Russell 2000 Index focuses on small-cap companies [2] - Membership in the Russell Indexes lasts for one year and results in automatic inclusion in appropriate growth and value style indexes, which are utilized by investment managers and institutional managers [2] Group 2 - aTyr is a clinical stage biotechnology company that focuses on developing first-in-class medicines from its proprietary tRNA synthetase platform [4] - The company's lead therapeutic candidate is efzofitimod, which is in clinical development for treating interstitial lung disease, a group of immune-mediated disorders [4]